Zevalin-beam for Aggressive Lymphoma

NCT ID: NCT00491491

Last Updated: 2020-08-31

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 60 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-06-30
• Study Completion Date: 2015-02-28

Brief Summary

The study hypothesis is that the addition of zevalin radioimmunotherapy to the conditioning regimen given prior to BEAM high-dose chemotherapy and autologous stem cell transplantation in patients with aggressive lymphoma will reduced disease recurrence rate and improve overall and disease-free survival.

Conditions

Non-Hodgkin's Lymphoma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Z-BEAM

ibritumomab tiuxetan (zevalin) BEAM

Group Type: EXPERIMENTAL

ibritumomab tiuxetan

Intervention Type: DRUG

0.4 mCi/kg

BEAM chemotherapy and autologous stem-cell transplantation

Intervention Type: PROCEDURE

standard BEAM

standard BEAM chemotherapy

Group Type: ACTIVE_COMPARATOR

BEAM chemotherapy and autologous stem-cell transplantation

Intervention Type: PROCEDURE

Interventions

ibritumomab tiuxetan

0.4 mCi/kg

Intervention Type: DRUG

BEAM chemotherapy and autologous stem-cell transplantation

Intervention Type: PROCEDURE

Other Intervention Names

zevalin

Eligibility Criteria

Inclusion Criteria

1. Patients with CD20 positive diffuse large B-cell lymphoma as confirmed by a pathological biopsy report.

2. Patients who are candidates for autologous stem-cell transplantation due to primary refractory or first relapse of disease.

3. Patients must have chemo-sensitive disease achieving at least partial response (Cheson 2007 criteria) to last chemotherapy.

4. Age ≥ 18 years and age ≤ 70

5. Patients with adequate autologous stem cell collection for transplantation (target ≥ 2.5 x 106 CD34+ cells/kg).

6. Patients must sign written informed consent.

7. Adequate birth control in fertile patients.

8. All prior chemotherapy completed at least three weeks before study treatment.

9. Marrow involvement less than 25% at transplantation, no limitation on blood counts (low platelet count allowed).

10. Negative HIV antibody.

Exclusion Criteria

1. 1. Chemo-refractory disease as determined by less than partial response (Cheson 2007 Criteria) to last chemotherapy.

2. Two or more relapses after initial response to induction chemotherapy.

3. High-grade transformation from earlier diagnosis of low-grade lymphoma. Patients with "De Novo" Transformed DLBCL, defined as DLBCL only on lymph node biopsy and a discordant marrow with para-trabecular small cells at first diagnosis of lymphoma, are eligible if adherent all other selection criteria.

4. Bilirubin > 3.0 mg/dl, transaminases > 3 times upper normal limit.

5. Creatinine > 2.0 mg/dl.

6. ECOG Performance status > 2.

7. Uncontrolled infection.

8. Pregnancy or lactation.

9. Abnormal lung diffusion capacity (DLCO < 40% predicted).

10. Severe cardiovascular disease; New York Heart Association (NYHA) Functional Classification ≥2.

11. Active CNS disease involvement.

12. Presence of any other malignancy or history of prior malignancy within 5 years of study entry. Within 5 years, patients treated for Stage I or II cancers are eligible provided they have a life expectancy > 5 years in relation to this prior malignance. The 5-year exclusion rule does not apply to-non melanoma skin tumors and in situ cervical cancer.

13. Pleural effusion or ascites > 1 liter.

14. Known hypersensitivity to rituximab.

15. Psychiatric conditions/disease that impair the ability to give informed consent or to adequately co-operate.

16. Prior radioimmunotherapy.

17. Prior autologous or allogeneic HSCT.

18. Active evidence of Hepatitis B or C infection; Hepatitis B surface antigen positive.

19. Patients who have had prior radiation to the lung will be excluded from the study, although mediastinal irradiation will be permitted if minimal lung is in the treatment volume.

20. Patients who have received >500cGy radiation to the kidneys will be excluded from the study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

City of Hope Medical Center

OTHER

Sponsor Role: collaborator

Amsterdam UMC, location VUmc

OTHER

Sponsor Role: collaborator

University of Göttingen

OTHER

Sponsor Role: collaborator

Sheba Medical Center

OTHER_GOV

Sponsor Role: lead

Responsible Party

Dr. Avichai Shimoni MD

Dr. Avichai Shimoni

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Avichai Shimoni, MD

Role: STUDY_CHAIR

Chaim Sheba Medical Center, Tel Hashomer, Israel

Amrita Krishnan, MD

Role: STUDY_CHAIR

City of Hope National Medical Center, Duarte, CA

Locations

Mayo Clinic Arizona

Scottsdale, Arizona, United States

City of Hope National Medical Center

Duarte, California, United States

Cedars Sinai Medical Center

Los Angeles, California, United States

Moffitt Cancer Center

Tampa, Florida, United States

Northwestern University

Chicago, Illinois, United States

Mayo Clinic

Rochester, Minnesota, United States

Georg-August Universität

Göttingen, , Germany

Chaim Sheba Medical Center

Tel Litwinsky, , Israel

VU Medical Center

Amsterdam, , Netherlands

Countries

United States; Germany; Israel; Netherlands

Other Identifiers

SHEBA-07-4466-AN-CTIL

Identifier Type: -

Identifier Source: org_study_id